"Receptors, Cytokine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Cell surface proteins that bind cytokines and trigger intracellular changes influencing the behavior of cells.
| Descriptor ID |
D018121
|
| MeSH Number(s) |
D12.776.543.750.705.852
|
| Concept/Terms |
Receptors, Cytokine- Receptors, Cytokine
- Cytokine Receptors
- Cytokine Receptor
- Receptor, Cytokine
- Receptors, Cytokines
- Cytokines Receptors
|
Below are MeSH descriptors whose meaning is more general than "Receptors, Cytokine".
Below are MeSH descriptors whose meaning is more specific than "Receptors, Cytokine".
- Receptors, Cytokine
- Receptors, Chemokine
- Receptors, Colony-Stimulating Factor
- Receptors, Interferon
- Receptors, Interleukin
- Receptors, Oncostatin M
- Receptors, OSM-LIF
- Receptors, Thrombopoietin
- Receptors, Transforming Growth Factor beta
- Receptors, Tumor Necrosis Factor
This graph shows the total number of publications written about "Receptors, Cytokine" by people in this website by year, and whether "Receptors, Cytokine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 |
| 1996 | 1 | 0 | 1 |
| 1997 | 2 | 0 | 2 |
| 1998 | 0 | 3 | 3 |
| 1999 | 2 | 1 | 3 |
| 2000 | 0 | 2 | 2 |
| 2001 | 0 | 1 | 1 |
| 2002 | 2 | 1 | 3 |
| 2003 | 0 | 1 | 1 |
| 2004 | 1 | 0 | 1 |
| 2005 | 1 | 1 | 2 |
| 2006 | 0 | 2 | 2 |
| 2009 | 1 | 0 | 1 |
| 2010 | 0 | 2 | 2 |
| 2011 | 0 | 1 | 1 |
| 2012 | 2 | 0 | 2 |
| 2013 | 1 | 0 | 1 |
| 2014 | 0 | 1 | 1 |
| 2016 | 1 | 0 | 1 |
| 2017 | 0 | 3 | 3 |
| 2018 | 0 | 1 | 1 |
| 2019 | 0 | 1 | 1 |
| 2020 | 0 | 1 | 1 |
| 2022 | 0 | 2 | 2 |
| 2023 | 0 | 1 | 1 |
| 2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Receptors, Cytokine" by people in Profiles.
-
Co-targeting of the thymic stromal lymphopoietin receptor to decrease immunotherapeutic resistance in CRLF2-rearranged Ph-like and Down syndrome acute lymphoblastic leukemia. Leukemia. 2025 Mar; 39(3):555-567.
-
Modular chimeric cytokine receptors with leucine zippers enhance the antitumour activity of CAR T cells via JAK/STAT signalling. Nat Biomed Eng. 2024 Apr; 8(4):380-396.
-
Preclinical development of 1B7/CD3, a novel anti-TSLPR bispecific antibody that targets CRLF2-rearranged Ph-like B-ALL. Leukemia. 2023 10; 37(10):2006-2016.
-
Outcomes of adult patients with relapsed/refractory CRLF2 rearranged B-cell acute lymphoblastic leukemia. Am J Hematol. 2023 06; 98(6):E142-E144.
-
CRLF2 overexpression results in reduced B-cell differentiation and upregulated E2F signaling in the Dp16 mouse model of Down syndrome. Exp Hematol. 2022 06; 110:34-38.
-
Noncoding genetic variation in GATA3 increases acute lymphoblastic leukemia risk through local and global changes in chromatin conformation. Nat Genet. 2022 02; 54(2):170-179.
-
From the archives of MD Anderson Cancer Center: Concurrent BCR-ABL1 and CRLF2 rearrangements in B-lymphoblast phase of chronic myeloid leukemia. Ann Diagn Pathol. 2021 Aug; 53:151767.
-
Engineered Cytokine Signaling to Improve CAR T Cell Effector Function. Front Immunol. 2021; 12:684642.
-
Outcomes in patients with CRLF2 overexpressed acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2021 07; 56(7):1746-1749.
-
GATA3 rs3824662A allele in B-cell acute lymphoblastic leukemia in adults, adolescents and young adults: association with CRLF2 rearrangement and poor prognosis. Am J Hematol. 2021 03 01; 96(3):E71-E74.